Pfizer Inc. asked U.S. regulators to clear its Covid-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.
The drugmaker and
Pfizer and BioNTech
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.